Clinical trials: Continuous Glucose Monitoring
Primary Adrenal Insufficiency, Intermittent Fasting
Risks of Intermittent Fasting in Patients With Primary Adrenal Insufficiency
In primary adrenal insufficiency, there is an increased risk of hypoglycaemia and dehydration. These risks have been little studied particularly during intermittent fasting.
- Trial name
- NCT06299020
- Testing
- intermittent fasting
- Where
- Tunisia
- Volunteers
- 30 people
- Sponsor
- Hopital La Rabta
Diabetes Mellitus
Evaluation of the Safety and Effectiveness of the Dexcom Continuous Glucose Monitoring (CGM) System
Evaluation of the Safety and Effectiveness of the Dexcom Glucose Monitoring (CGM) System
- Trial name
- NCT04794478
- Testing
- Dexcom Continuous Glucose Monitoring System
- Where
- 12 sites in United States
- Volunteers
- 482 people
- Sponsor
- DexCom, Inc.
Critical Illness, Metabolism Disorders
Development of a Novel Algorithm for Real-Time Bedside Assessment of Insulin Resistance in Critically Ill Patients Based on Continuous Glucose Monitoring Data
This study aims to develop and validate a novel algorithm for the real-time assessment of insulin resistance in critically ill patients using Continuous Glucose Monitoring (CGM).
- Conditions
- Critical Illness, Metabolism Disorders, Insulin Resistance
- Trial name
- NCT07385391
- Where
- China
- Volunteers
- 179 people
- Sponsor
- Chinese Medical Association
Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes
Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes
The investigators are hoping to determine whether tailoring the diet of someone with type 2 diabetes to their ethnic group while following American Diabetes Association guidelines can make a significant difference in their blood…
- Trial name
- NCT06836479
- Testing
- NOURISH Diet, Self-Selected Diet (Control)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Pre-diabetes
Continuous Glucose Monitoring (CGM) in Prediabetes
Part 1 and 2 of study (For Patient Participants) The purpose of this study is to examine if the wearing of a medical device called a continuous glucose monitor (CGM) can guide adults with prediabetes modify their behaviors and…
- Trial name
- NCT07371546
- Testing
- Continuous Glucose Monitoring
- Where
- 2 sites in Singapore
- Volunteers
- 76 people
- Sponsor
- SingHealth Polyclinics
Diabetes Mellitus, Type 1
The GlucoPred Investigation II
Diabetes mellitus type 1 (DM1) is an autoimmune metabolic disease in which the insulin producing cells in the pancreas are destroyed and the subject is left totally dependent of external supply of insulin.
- Trial name
- GPI-II (NCT02595580)
- Testing
- Glucopred
- Where
- 2 sites in Norway
- Volunteers
- 16 people
- Sponsor
- Norwegian University of Science and Technology
Surgery--Complications
Accuracy of the Dexcom G6 Continuous Glucose Monitoring System Following Cardiac Surgery
This is a prospective longitudinal study to study the agreement between a novel continuous glucose monitoring system (CGMS) versus current blood glucose monitoring.
- Trial name
- NCT04569240
- Testing
- Dexcom G6 continuous glucose monitor
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The Cleveland Clinic
Diabetes, Type 2 Diabetes (T2DM)
CGM Use in Non-insulin Patients With DM2
The U.S. Food and Drug Administration (FDA) has approved multiple Continuous Glucose Monitoring (CGM) devices from different manufacturers to be used as an aide in patients with type 1 and type 2 diabetes who require medications…
- Conditions
- Diabetes, Type 2 Diabetes (T2DM), Obesity Type 2 Diabetes Mellitus, Non Insulin Dependent Diabetes Mellitus
- Trial name
- CGM-DWI (NCT07128342)
- Testing
- CGM Group, FSBG group
- Volunteers
- 100 people
- Sponsor
- Milwaukee VA Medical Center
Continuous Glucose Monitoring
The Use of a Continuous Glucose Monitoring System (Dexcom G6) in Hospitalized Patients for Acute Care
The state of a coronavirus disease pandemic (COVID-19) was declared by the World Health Organization on March 11, 2020. Hospitalized patients receiving intravenous (IV) insulin therapy have been identified in the hospital setting…
- Trial name
- NCT04385862
- Where
- Canada
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)